Qiagen grounds drug discovery agents in curated knowledge

Qiagen is making a fairly blunt argument: in drug discovery, the model is not the whole story. The company says agents are only as useful as the knowledge underneath them, and that knowledge needs provenance, context, and human curation if biopharma teams are going to trust the answers.

That idea came through in a conversation between Iman Bhattacharya, Qiagen’s senior global product marketing manager, and theCUBE Research’s John Furrier at GraphSummit. Bhattacharya’s message was simple. Qiagen is focused less on the flash of the AI layer and more on the quality of the knowledge foundation beneath it.

The bioinformatics side of the company has been manually curating biomedical data for more than 25 years, with more than 150 MD- and PhD-level experts doing the work. That curated base now sits under the Qiagen Discovery Platform, which adds Model Context Protocol access and an agentic Discovery Explorer on top. Qiagen also teamed with Nvidia in May to push graph-based AI for drug discovery.

And the company is treating that stack as a system, not a side project. Bhattacharya said the aim is to fit into the wider ecosystem rather than become another silo. That matters because in pharma, speed without accuracy is just expensive noise.

His warning about agents was direct: they can hallucinate, they won’t politely stop to say no, and they can spit out synthetic results that look plausible until someone checks the source. For customers chasing accurate indications ahead of rivals, traceable output is the point. Not clever guesses.